MJFF

RaceTrac Adds Java Jolt to Parkinson’s Research Funding and Awareness with 13th Annual ‘Coffee For A Cause’ Week

Retrieved on: 
Wednesday, March 27, 2024
Disease, Partnership, Patient, Research, MJFF, Truist Park, Pathology, RaceTrac, Family

Fox Foundation (MJFF) by offering ‘Coffee For A Cause’ week beginning Sunday, April 14, to help raise money and awareness for Parkinson’s research.

Key Points: 
  • Fox Foundation (MJFF) by offering ‘Coffee For A Cause’ week beginning Sunday, April 14, to help raise money and awareness for Parkinson’s research.
  • Since 2011, RaceTrac has raised more than $8 million to support Parkinson’s research through its ‘Coffee For A Cause’ week and annual Run For Research 5K, scheduled for Saturday, September 14, 2024.
  • All proceeds raised during RaceTrac’s ‘Coffee For A Cause’ week, between April 14 and April 20, will be donated directly to the Foundation.
  • For information on the amazing research currently underway and for additional resources and support for those living with Parkinson’s disease, visit michaeljfox.org .

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 25, 2024
Research, Diabetic nephropathy, Cholesterol, Obesity, Institutional review board, Patient, Protocol, MJFF, University, IND, IRB, Investigational New Drug, Therapy, Atherosclerosis, Metabolic syndrome, Government, Inflammasome, Pharmaceutical industry

WESTON, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for full year ending December 31, 2023, and provides business update.

Key Points: 
  • Scientific collaboration to assess Inflammasome ASC Inhibitor IC 100 as a potential treatment for atherosclerosis expected to conclude H1-2024.
  • WESTON, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for full year ending December 31, 2023, and provides business update.
  • “Throughout 2023 and early 2024, ZyVersa achieved considerable progress in advancing development of our two lead candidates.
  • The impairment is a result of the decline in stock value and the resulting market capitalization of ZyVersa during the 2023 Period.

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, March 14, 2024
University of Geneva, Diagnosis, Target, Down syndrome, MSA, Disease, ALS, PD, Safety, Multiple system atrophy, Patient, PET, Research, Geneva University Hospitals, Amyloid beta, MJFF, ABATE, Smith, University, KOL, Doctor of Philosophy, MD, TAR, IND, Medicine, AC, University of Luxembourg, Cognition, DS, Johnson & Johnson, Janssen, Sahlgrenska University Hospital, CHF, Injection, DSMB, University of Gothenburg, Food, RETAIN, Janssen Pharmaceuticals, Nature Communications, Pharmaceutical industry

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.
  • Six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and 12-month Abeta-PET data are expected in H2 2024.
  • Comm., 2023) showed that AC Immune’s wholly-owned a-syn-PET tracer ACI-12589 can detect a-syn pathology in multiple system atrophy (MSA) and differentiate MSA from other a-synucleinopathies.
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and Life Molecular Imaging.

Rumble Boxing Joins the Fight with The Michael J. Fox Foundation

Retrieved on: 
Wednesday, April 3, 2024
Philanthropy, Health, Sports, Neurology, Fitness & Nutrition, Boxing, Foundation, PDT, Disease, Partnership, Research, Perspiration, MJFF, Introduction, Fitness, Parkinson's disease, House, Courage, DSM-IV codes, HIIT, Rumble, Multimedia

Rumble Boxing , an Xponential Fitness brand, announced today its continued partnership for the second consecutive year with Team Fox, the grassroots fundraising community of The Michael J.

Key Points: 
  • Rumble Boxing , an Xponential Fitness brand, announced today its continued partnership for the second consecutive year with Team Fox, the grassroots fundraising community of The Michael J.
  • Fox Foundation for Parkinson’s Research (MJFF) to raise funds and garner support for Parkinson’s Awareness Month in April.
  • To amplify the impact, Rumble Boxing is excited to present a multi-city panel tour with Rumble Boxing Co-Founder, Noah Neiman, alongside MJFF community members affected by Parkinson’s.
  • With over 80 studios nationwide, Rumble Boxing pairs boxing, HIIT, metabolic conditioning, and strength training group fitness for a full-body workout for all fitness levels.

Stephen Grubb, Senior Vice President of Finance at The Michael J. Fox Foundation, Recognized on Crain's New York Business Notable Leaders in Finance List

Retrieved on: 
Friday, March 22, 2024
A Place for Us, Growth, PD, Partnership, Research, MJFF, Parkinson's disease, Senior

Fox Foundation for Parkinson's Research (MJFF) announces recognition of its Senior Vice President of Finance, Stephen Grubb, on this week's Crain's New York Business "2024 Notable Leaders in Finance" publication.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF) announces recognition of its Senior Vice President of Finance, Stephen Grubb, on this week's Crain's New York Business "2024 Notable Leaders in Finance" publication.
  • The list recognizes leaders in the finance industry who have a proven track record of success and impact within the greater New York City community through their professional achievements and broader acts of service.
  • Grubb has played a significant role in enhancing the Foundation's operational finance strategies that further enable the Foundation's funding toward promising research.
  • View the entire list of 52 finance professionals selected as part of the Crain's list here.

The Global Parkinson's Genetics Program and Psomagen Inc. Make Agreement with Goal to Transform Parkinson's Disease Genetics Research and Patient Outcomes

Retrieved on: 
Monday, March 18, 2024
WGS, Organization, ASAP, Parkinson's disease, Coalition, Disease, KOSDAQ, PD, Genetics, Patient, Research, MJFF, Science, CAP, Doctor of Philosophy, Laboratory, CLIA, Whole genome sequencing, Bangladesh Technical Education Board, ISO

The program will run over the next 2.5 - 3 years using Illumina sequencing instruments and reagents.

Key Points: 
  • The program will run over the next 2.5 - 3 years using Illumina sequencing instruments and reagents.
  • GP2 is a program supported by the Aligning Science Across Parkinson's (ASAP) initiative managed by the Coalition for Aligning Science and implemented by The Michael J.
  • Fox Foundation for Parkinson's Research (MJFF) and is focused on improving our understanding of the genetic architecture of Parkinson's disease and making this knowledge globally relevant.
  • GP2 specifically has the goal of including groups traditionally underrepresented in genetics research, to diversify its understanding of PD by focusing on inclusion in the research pipeline.

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

Retrieved on: 
Thursday, March 7, 2024
PD, Research, Doctor of Philosophy, SVP, Cerebrospinal fluid, Conference, MJFF, Mayo Clinic, Clinical professor, Patient, CSF, Synucleinopathy, Pharmaceutical industry

UB-312 is the first active immunotherapy candidate to show reduction of pathological alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of PD patients.

Key Points: 
  • UB-312 is the first active immunotherapy candidate to show reduction of pathological alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of PD patients.
  • UB-312 is designed to target aggregated forms of aSyn, the toxic species that underlies PD and other synucleinopathies.
  • As part of the randomized, double-blind, placebo-controlled Phase 1 clinical trial, The Michael J.
  • “Currently, there are no treatments that address the underlying conditions of Parkinson’s, and we are very excited about this target engagement data.

bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Professional Services, Health, Philanthropy, Pharmaceutical, Other Science, Research, Fund Raising, Genetics, Science, Finance, PD, Dopaminergic, Partnership, Neuron, Amnesia, Culture, TF, DSM-IV codes, Tremor, MJFF, Speed, Depression

bit.bio, the company coding human cells for novel cures, today announces the first project within a multi-year collaboration agreement with The Michael J.

Key Points: 
  • bit.bio, the company coding human cells for novel cures, today announces the first project within a multi-year collaboration agreement with The Michael J.
  • Fox Foundation for Parkinson's Research (MJFF) to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease (PD).
  • Under the terms of the collaboration agreement, both wild type human cells and physiologically relevant disease model cells can be generated through individual project agreements.
  • “We are thrilled to partner with bit.bio and to leverage the company’s unique platform for the generation of human cells.

National Institute for Fitness and Sport Invites Senior Living Communities to Pump It for Parkinson's on April 11, 2024

Retrieved on: 
Thursday, February 15, 2024
Parkinson's disease, Marketing, Indiana University, Research, Multimedia, Education, Exercise, T6, Learning, James Parkinson, Disease, MJFF, Health, Fitness, Physical fitness, Pump

INDIANAPOLIS, Feb. 15, 2024 /PRNewswire-PRWeb/ -- The National Institute for Fitness and Sport (NIFS) presents the second running of Pump it for Parkinson's on World Parkinson's Day, April 11, 2024. NIFS has partnered with NuStep inviting senior living communities across the country to take part in this event to raise awareness on the benefits of exercise for individuals with Parkinson's. Communities can participate by rallying their residents and staff to track steps taken on their NuStep machine to contribute to NIFS nationwide goal of achieving 10 million steps honoring the 10 million people living worldwide with the disease. Registration is free and NIFS will provide communities with a digital toolkit including tracking forms, promotional content, and educational resources they need to get their residents excited.

Key Points: 
  • The National Institute for Fitness and Sport (NIFS) presents the second running of Pump it for Parkinson's on World Parkinson's Day, April 11, 2024.
  • INDIANAPOLIS, Feb. 15, 2024 /PRNewswire-PRWeb/ -- The National Institute for Fitness and Sport (NIFS) presents the second running of Pump it for Parkinson's on World Parkinson's Day, April 11, 2024.
  • This will allow Pump it for Parkinson's to reach several generations with Parkinson's education beyond senior living communities alone and aligns with NIFS nonprofit mission.
  • National Institute for Fitness and Sport is a non-profit organization committed to enhancing human health, physical fitness, and athletic performance through research, education, and service.

H1 Honored With Spot On the New York Digital Health 100 For Third Straight Year

Retrieved on: 
Thursday, February 8, 2024
MJFF, Digital health, Digital, Clinical trial, Research, Pharmaceutical industry

Digital Health New York (DHNY) publishes the annual list in conjunction with the New York Healthcare Innovation Report , which takes an in-depth look at the investment trends, opportunities, and challenges in the digital health sector.

Key Points: 
  • Digital Health New York (DHNY) publishes the annual list in conjunction with the New York Healthcare Innovation Report , which takes an in-depth look at the investment trends, opportunities, and challenges in the digital health sector.
  • This is the third consecutive year that H1 has received this honor.
  • “It’s an honor to be recognized by DHNY as a top digital health company for the third year in a row,” said Ariel Katz , co-founder and CEO at H1.
  • Our team is grateful to be recognized for these efforts.”
    “2024 marks the fifth year of the New York Digital Health 100, and in that time, the digital health ecosystem in New York has significantly grown and evolved,” said Bunny Ellerin, co-founder and CEO of DHNY.